Outlook Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $129.0M
- Price
- $0.6901
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.41%
- Volume
- 20.8M
About
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Quick stats
Shares outstanding187.0M
Computed float83.0M
Float / shares44.4%
Cash runway (months)-1.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001649989
AI Summary
AI-generated1/44
majorbullishearnings
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Outlook Therapeutics reported a narrower adjusted net loss of $10.9 million, or $0.09 per share, for the third quarter of fiscal 2026, compared to an adjusted net loss of $15.8 million a year ago. GAAP net loss was $20.3 million, or $0.15 per share.
The company is advancing the U.S. commercial launch of LYTENAVA, the only FDA-approved ophthalmic bevacizumab, with rollout planned by the end of calendar 2026. Management believes the product has the potential to exceed $500 million in annual U.S. sales by 2030.
Subsequent to the quarter end, the company closed a public offering raising approximately $51.1 million in net proceeds to support the launch, ending the quarter with $11.2 million in cash.
Red flags
- Revenue dropped to $9,000 from $1.5 million in the prior year period